Abstract
It is of interest in some applications to determine whether there is a relationship between a hazard rate function (or a cumulative incidence function) and a mark variable which is only observed at uncensored failure times. We develop nonparametric tests for this problem when the mark variable is continuous. Tests are developed for the null hypothesis that the mark-specific hazard rate is independent of the mark versus ordered and two-sided alternatives expressed in terms of mark-specific hazard functions and mark-specific cumulative incidence functions. The test statistics are based on functionals of a bivariate test process equal to a weighted average of differences between a Nelson–Aalen-type estimator of the mark-specific cumulative hazard function and a nonparametric estimator of this function under the null hypothesis. The weight function in the test process can be chosen so that the test statistics are asymptotically distribution-free. Asymptotically correct critical values are obtained through a simple simulation procedure. The testing procedures are shown to perform well in numerical studies, and are illustrated with an AIDS clinical trial example. Specifically, the tests are used to assess if the instantaneous or absolute risk of treatment failure depends on the amount of accumulation of drug resistance mutations in a subject's HIV virus. This assessment helps guide development of anti-HIV therapies that surmount the problem of drug resistance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E.-E. Aly, S. C. Kochar, and I. W. McKeague, “Some tests for comparing cumulative incidence functions and cause-specific hazard rates,” J. Am. Statist. Assoc. vol. 89 pp. 994–999, 1994.
P. K. Andersen, O. Borgan, N. Keiding, and R. Gill, Statistical Models Based on Counting Processes, Springer: New York, 1993.
P. J. Bickel and M. J. Wichura, “Convergence criteria for multiparameter stochastic processes and some applications,” Ann. Math. Statist. vol. 42 pp. 1656–1670, 1971.
Y. Bilias, M. Gu, and Z. Ying, “Towards a general asymptotic theory for Cox model with staggered entry,” Ann. Statist. vol. 25 pp. 662–682, 1997.
P. Billingsley, Convergence of Probability Measures, Wiley: New York, 1968.
R. T. D'Aquila, M. D. Hughes, V. A. Johnson, M. A. Fischl, J.-P. Sommadossi, S. Liou, J. Timpone, M. Myers, N. Basgoz, M. Niu, M. S. Hirsch, and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators, “Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection,” Ann. Int. Med. vol. 124 pp. 1019–1031, 1996.
J. P. Fine, “Analysing competing risks data with transformation models,” J. Roy. Statist. Soc. Ser. B vol. 61 pp. 817–830, 1999.
P. B. Gilbert, V. DeGruttola, S. M. Hammer, and D. R. Kuritzkes, “Virological and regimen termination surrogate endpoints in AIDS clinical trials,” J. Am. Med. Assoc. vol. 8 pp. 775–782, 2001a.
P. B. Gilbert, G. J. Hanna, V. De Gruttola, J. Martinez-Picado, D. R. Kuritzkes, V. A. Johnson, D. D. Richman, and R. T. D'Aquila, “Comparative analysis of HIV type 1 genotypic resistance across antiretroviral trial treatment regimens,” AIDS Res. Hum. Retroviruses vol. 16 pp. 1325–1336, 2000.
P. B. Gilbert, S. G. Self, M. Rao, A. Naficy, and J. D. Clemens, “Sieve analysis: Methods for assessing how vaccine efficacy depends on genotypic and phenotypic pathogen variation from vaccine trial data,” J. Clin. Epidemiol. vol. 54 pp. 68–85, 2001b.
H. F. Gunthard, A. J. Leigh-Brown, R. T. D'Aquila, V. A. Johnson, D. R. Kuritzkes, D. D. Richman, and J. K. Wong, “Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary resistance in HIV-1 pol,” Virology vol. 259 pp. 154–165, 1999.
G. J. Hanna, V. A. Johnson, D. R. Kuritzkes, D. D. Richman, A. J. Leigh-Brown, A. V. Savara, J. D. Hazelwood, and R. T. D'Aquila, “Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine,” J. Infect. Dis. vol. 181 pp. 904–911, 2000.
M. S. Hirsch, F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman, “Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel,” J. Am. Med. Assoc. vol. 283 pp. 2417–2426, 2000.
X. S. Hu and W. Y. Tsai, “Linear rank tests for competing risks model,” Statist. Sin. vol. 9 pp. 971–983, 1999.
Y. Huang and T. A. Louis, “Nonparametric estimation of the joint distribution of survival time and mark variables,” Biometrika vol. 85 pp. 785–798, 1998.
K. F. Lam, “A class of tests for the equality of k cause-specific hazard rates in a competing risks model,” Biometrika vol. 85 pp. 179–188, 1998.
A. J. Leigh-Brown, H. G. Gunthard, J. K. Wong, R. T. D'Aquila, V. A. Johnson, D. R. Kuritzkes, and D. D. Richman, “Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy,” J. Infect. Dis. vol. 180 pp. 1043–1049, 1999.
X. Luo and B. Turnbull, “Comparing two treatments with multiple competing risks endpoints,” Statist. Sin. vol. 9 pp. 985–997, 1999.
I. W. McKeague, A. M. Nikabadze, and Y. Sun, “An omnibus test for independence of a survival time from a covariate,” Ann. Statist. vol. 23 pp. 450–475, 1995.
I. W. McKeague and K. J. Utikal, “Identifying nonlinear covariate effects in semimartingale regression models,” Probab. Theory Rel. Fields vol. 87 pp. 1–25, 1990.
M. Olschewski and M. Schumacher, “Statistical analysis of quality of life in cancer clinical trials,” Statist. Med. vol. 9 pp. 749–763, 1990.
D. Pollard, Empirical Processes: Theory and Applications, NSF-CBMS Regional Conference Series in Probability and Statistics, 2. Institute of Mathematical Statistics, Hayward, CA, 1990.
R. L. Prentice, J. D. Kalbfleisch, A. V. Peterson, N. Flournoy, V. T. Farewell, and N. E. Breslow, “The analysis of failure times in the presence of competing risks,” Biometrics vol. 34 pp. 541–554, 1978.
G. R. Shorack and J. A. Wellner, Empirical Processes with Applications to Statistics, Wiley: New York, 1986.
Y. Sun, “Generalized nonparametric test procedures for comparing multiple cause-specific hazard rates,” J. Nonparametr. Statist. vol. 13 pp. 171–207, 2001.
Y. Sun and R. C. Tiwari, “Comparing cause-specific hazard rates of a competing risks model with censored data,” in Analysis of Censored Data, (H. L. Koul and J. V. Deshpandé, eds.) IMS Lecture Notes-Monograph Series vol. 27 pp. 255–270, 1995.
A. A. Tsiatis, “A nonidentifiability aspect of the problem of competing risks,” Proc. Nat. Acad. Sci. USA vol. 72 pp. 20–22, 1975.
UNAIDS, Report from a Meeting of the WHO-UNAIDS Vaccine Advisory Committee, “Approaches to the development of broadly protective HIV vaccines: Challenges posed by genetic, biological and antigenic variability of HIV-1,” AIDS vol. 15 pp. W1–W25, 2001.
A. W. Van der Vaart and J. A. Wellner, Weak Convergence and Empirical Processes with Applications to Statistics, Springer: New York, 1996.
P. G. Yeni, S. M. Hammer, C. C. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding, “Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel,” J. Am. Med. Assoc. vol. 288 pp. 222–235, 2002.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gilbert, P.B., Mckeague, I.W. & Sun, Y. Tests for Comparing Mark-Specific Hazards and Cumulative Incidence Functions. Lifetime Data Anal 10, 5–28 (2004). https://doi.org/10.1023/B:LIDA.0000019253.69537.91
Issue Date:
DOI: https://doi.org/10.1023/B:LIDA.0000019253.69537.91